Rapport Therapeutics (NASDAQ:RAPP) Stock Lifted to “Hold” by Wall Street Zen

Wall Street Zen upgraded shares of Rapport Therapeutics (NASDAQ:RAPP) from a sell rating to a hold rating in a research note published on Saturday,Wall Street Zen reports.

A number of other brokerages have also recently commented on RAPP. JonesTrading upped their price target on shares of Rapport Therapeutics from $50.00 to $82.00 and gave the company a “buy” rating in a research note on Wednesday, October 21st. Wolfe Research initiated coverage on shares of Rapport Therapeutics in a research note on Thursday, October 15th. They issued an “outperform” rating and a $50.00 price objective for the company. Citigroup reiterated an “outperform” rating on shares of Rapport Therapeutics in a research note on Tuesday, October 20th. Wells Fargo & Company lowered their target price on shares of Rapport Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a report on Thursday. Finally, HC Wainwright restated a “buy” rating and set a $66.00 target price on shares of Rapport Therapeutics in a research report on Tuesday, October 20th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $64.50.

Rapport Therapeutics Stock Up 3.0%

NASDAQ RAPP opened at $24.44 on Friday. The company has a market cap of $1.45 billion, a PE ratio of -7.71 and a beta of 1.40. Rapport Therapeutics has a 52 week low of $22.06 and a 52 week high of $52.93. The firm’s 50-day simple moving average is $34.16 and its two-hundred day simple moving average is $35.53.

Rapport Therapeutics (NASDAQ:RAPP) last posted its earnings results on Wednesday, November 4th. The company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($1.20) by $0.36. As a group, equities research analysts anticipate that Rapport Therapeutics will post -3.34 EPS for the current year.

Insider Buying and Selling

In other Rapport Therapeutics news, Director Paul M. Silva acquired 3,680 shares of the company’s stock in a transaction that occurred on Thursday, October 22nd. The stock was bought at an average price of $27.07 per share, with a total value of $99,617.60. Following the completion of the purchase, the director owned 3,680 shares of the company’s stock, valued at approximately $99,617.60. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ramiro Sanchez bought 3,600 shares of Rapport Therapeutics stock in a transaction that occurred on Friday, October 23rd. The shares were acquired at an average price of $27.35 per share, with a total value of $98,460.00. Following the completion of the transaction, the director owned 3,600 shares of the company’s stock, valued at $98,460. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have bought 1,031,174 shares of company stock valued at $22,023,898 and have sold 97,976 shares valued at $4,391,729. 12.48% of the stock is currently owned by corporate insiders.

Institutional Trading of Rapport Therapeutics

Large investors have recently modified their holdings of the business. Algert Global LLC purchased a new position in Rapport Therapeutics in the 2nd quarter worth approximately $9,327,000. Johnson & Johnson purchased a new stake in shares of Rapport Therapeutics during the 2nd quarter valued at $74,360,823. Legal & General Group Plc purchased a new stake in shares of Rapport Therapeutics during the 2nd quarter valued at $940,000. Bank of America Corp DE bought a new stake in shares of Rapport Therapeutics during the 2nd quarter worth $3,170,000. Finally, Walleye Capital LLC bought a new stake in shares of Rapport Therapeutics during the 2nd quarter worth $4,257,000.

Key Stories Impacting Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts across 2026–2030, implying smaller projected losses than previously expected. For example, its FY2027 estimate improved to a loss of $4.29 per share from $6.80, and its FY2028 estimate to a loss of $5.37 from $8.40. The firm reiterated its Buy rating and $66 price target. Better loss expectations could support investor sentiment. Rapport Therapeutics analyst estimates
• Negative Sentiment: UBS lowered its price target to $64 from $71, though it maintained a Buy rating. The reduced target is a negative revision, even as UBS continues to see potential upside. UBS price-target update

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.